Interestingly, we found that Syn treatment improved the integrity of the intestinal barrier and reduced serum LPS, TLR4/NF-κB signaling pathway activity, and inflammation in the AIH mouse model. This evidence concerns the gene TLR4 and autoimmune hepatitis.